Xingyuan Environment Technology's subsidiary, Xing'ao Environment, signs debt transfer agreement.
Xingyuan Environment (300266.SZ) announced that its controlling subsidiary, Aohan Xing'ao Environment Development Co., Ltd. (hereinafter referred to as "Xing'ao Environment"), intends to sign a "Debt Assignment Agreement" and a "Supplementary Agreement" with Chifeng Xinghui Transportation Development Co., Ltd. (hereinafter referred to as "Xinghui Transportation"). The agreements stipulate that Xing'ao Environment will transfer all remaining debts owned by the PPP project for the upgrade and transformation of the Aohan Flag City Complex and ecological protection construction project to Xinghui Transportation. Xinghui Transportation agrees to accept the debt and obtain all rights and related benefits to the debt.
Xingyuan Environment Technology (300266.SZ) announced that its holding subsidiary, Aohan Xing'ao Environment Development Co., Ltd. (hereinafter referred to as "Xing'ao Environment"), plans to sign a "Debt Transfer Agreement" and "Supplementary Agreement" with Chifeng Xinghui Transportation Development Co., Ltd. (hereinafter referred to as "Xinghui Transportation"). The agreements stipulate that Xing'ao Environment will transfer all remaining debts owned by the Aohan Qi City Complex Transformation and Ecological Protection Construction PPP project to Xinghui Transportation, and Xinghui Transportation agrees to acquire the debts and obtain all rights and related benefits.
This debt transfer will better mitigate the company's debt risks, improve cash flow, reduce bad debt losses, and enhance the company's financial condition. Based on preliminary calculations, including the discount amount of the debt and the bad debt losses already provided by the company, this debt transfer is expected to increase the company's income by 946,700 yuan.
Related Articles

Pharmaron Beijing (03759) plans to build a project in Shaoxing that would produce 200 tons of pharmaceutical intermediates and APIs annually.

CONSUN PHARMA (01681) plans to carry out a share buyback program.

Pharmaron Beijing (03759) plans to invest approximately 2 billion yuan to establish a new drug commercial production and CDMO research and development production service base in Qiantang District, Hangzhou City.
Pharmaron Beijing (03759) plans to build a project in Shaoxing that would produce 200 tons of pharmaceutical intermediates and APIs annually.

CONSUN PHARMA (01681) plans to carry out a share buyback program.

Pharmaron Beijing (03759) plans to invest approximately 2 billion yuan to establish a new drug commercial production and CDMO research and development production service base in Qiantang District, Hangzhou City.






